Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Köhler, Viktoria Florentine [VerfasserIn]   i
 Adam, Pia [VerfasserIn]   i
 Fuß, Carmina Teresa [VerfasserIn]   i
 Jiang, Linmiao [VerfasserIn]   i
 Berg, Elke [VerfasserIn]   i
 Frank-Raue, Karin [VerfasserIn]   i
 Raue, Friedhelm [VerfasserIn]   i
 Hoster, Eva [VerfasserIn]   i
 Knösel, Thomas [VerfasserIn]   i
 Schildhaus, Hans-Ulrich [VerfasserIn]   i
 Negele, Thomas [VerfasserIn]   i
 Siebolts, Udo [VerfasserIn]   i
 Lorenz, Kerstin [VerfasserIn]   i
 Allelein, Stephanie [VerfasserIn]   i
 Schott, Matthias [VerfasserIn]   i
 Spitzweg, Christine [VerfasserIn]   i
 Kroiß, Matthias [VerfasserIn]   i
Titel:Treatment of RET-positive advanced medullary thyroid cancer with multi-tyrosine kinase inhibitors
Titelzusatz:a retrospective multi-center registry analysis
Verf.angabe:by Viktoria Florentine Koehler, Pia Adam, Carmina Teresa Fuss, Linmiao Jiang, Elke Berg, Karin Frank-Raue, Friedhelm Raue, Eva Hoster, Thomas Knösel, Hans-Ulrich Schildhaus, Thomas Negele, Udo Siebolts, Kerstin Lorenz, Stephanie Allelein, Matthias Schott, Christine Spitzweg and Matthias Kroiss on behalf of the German Study Group for Rare Malignant Tumors of the Thyroid and Parathyroid Glands
Jahr:2022
Umfang:15 S.
Fussnoten:medullary thyroid cancer; rearranged during transfection; variant; multi-tyrosine kinase inhibitor; survival; treatment outcome
Titel Quelle:Enthalten in: Cancers
Ort Quelle:Basel : MDPI, 2009
Jahr Quelle:2022
Band/Heft Quelle:14(2022), 14, Artikel-ID 3405, Seite 1-15
ISSN Quelle:2072-6694
Abstract:Background: RET (rearranged during transfection) variants are the most prevalent oncogenic events in medullary thyroid cancer (MTC). In advanced disease, multi-tyrosine kinase inhibitors (MKIs) cabozantinib and vandetanib are the approved standard treatment irrespective of RET status. The actual outcome of patients with RET-positive MTC treated with MKIs is ill described. Methods: We here retrospectively determined the RET oncogene variant status with a targeted DNA Custom Panel in a prospectively collected cohort of 48 patients with advanced MTC treated with vandetanib and/or cabozantinib at four German referral centers. Progression-free survival (PFS) and overall survival (OS) probabilities were estimated using the Kaplan-Meier method. Results: In total, 44/48 (92%) patients had germline or somatic RET variants. The M918T variant was found in 29/44 (66%) cases. In total, 2/32 (6%) patients with a somatic RET variant had further somatic variants, while in 1/32 (3%) patient with a germline RET variant, additional variants were found. Only 1/48 (2%) patient had a pathogenic HRAS variant, and no variants were found in 3 cases. In first-line treatment, the median OS was 53 (95% CI (95% confidence interval), 32-NR (not reached); n = 36), and the median PFS was 21 months (12-39; n = 33) in RET-positive MTC patients. In second-line treatment, the median OS was 18 (13-79; n = 22), and the median PFS was 3.5 months (2-14; n = 22) in RET-positive cases. Conclusions: RET variants were highly prevalent in patients with advanced MTC. The treatment results in RET-positive cases were similar to those reported in unselected cohorts.
DOI:doi:10.3390/cancers14143405
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.3390/cancers14143405
 kostenfrei: Volltext: https://www.mdpi.com/2072-6694/14/14/3405
 DOI: https://doi.org/10.3390/cancers14143405
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:medullary thyroid cancer
 multi-tyrosine kinase inhibitor
 rearranged during transfection
 survival
 treatment outcome
 variant
K10plus-PPN:1872039618
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69331124   QR-Code
zum Seitenanfang